Clear­side Bio los­es near­ly half its val­ue pre-mar­ket as lead eye drug fails piv­otal test

Eye drug de­vel­op­er Clear­side Bio­med­ical $CSLD said late-stage da­ta showed its ex­per­i­men­tal treat­ment, Xipere, did not in­duce an ad­di­tion­al ben­e­fit when used in tan­dem with …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER